Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting

41% of CSB-001 treated eyes gained ≥15 letters compared to 0% in the non-treatment arm 55% of CSB-001 treated eyes gained ≥10 letters compared to 5% in the non-treatment arm <p...